Genmab capital increase from employee warrants, shares remain active on Nasdaq
26.06.2026 - 15:45:26 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 15:45.
Genmab A/S (DK0010272202) has executed a small capital increase this month after employees exercised share warrants granted under incentive programs. According to a company announcement distributed via GlobeNewswire, the Nasdaq-listed biotech issued 185 new shares with cash proceeds of roughly 0.2 million Danish kroner.Company announcement on the June 16, 2026 capital increase
Details of the June capital increase
In the June 16, 2026 release, Genmab specified that the 185 new shares each carry a nominal value of 1 Danish krone and were subscribed at a price of 1,334.50 kroner per share, all in cash.Genmab capital increase announcement of June 16, 2026 The transaction was executed without preemptive rights for existing shareholders, consistent with the terms of the approved warrant programs.
Following registration of the new equity, Genmab reported a total nominal share capital of 62,353,252 kroner, corresponding to 62,353,252 shares and voting rights, each with a nominal value of 1 krone.Genmab capital increase announcement of June 16, 2026 The company stated that the disclosure was made pursuant to section 32 of the Danish Capital Markets Act, which governs transparency around changes in listed share capital.
How the Genmab shares trade in New York
Genmab’s primary equity trading venue for international investors remains the Nasdaq in New York, where the American depositary shares trade under the ticker GMAB. Market data compiled by MarketBeat show a closing price of 26.14 US dollars for the GMAB ADS on June 25, 2026, up 1.08 percent on the day.Nasdaq GMAB quote and profile on MarketBeat
A separate technical overview from TradingKey likewise reports a last close at 26.14 dollars for Genmab on June 25, 2026, implying a market capitalization in the area of 16.3 billion dollars based on the reported share count.Genmab GMAB technical snapshot on TradingKey The same source describes a neutral technical picture, with the shares trading between support at 24.13 dollars and resistance around 27.65 dollars.
Background and price data on Genmab
Key figures, disclosures and historical articles help investors follow how the Genmab shares react to capital changes and clinical news over time.
The products behind Genmab’s revenue
Genmab generates a significant part of its revenue from antibody-based cancer treatments, most prominently the anti-CD38 therapy daratumumab, which is commercialized by Johnson & Johnson under the Darzalex brand in multiple myeloma and related indications.Genmab overview of marketed antibody products and technologies In addition, the company co-develops and licenses newer antibody formats, including the bispecific antibody epcoritamab for certain B-cell lymphomas.
Where the Genmab shares trade today
Based on the latest available Nasdaq data, the Genmab American depositary shares (DK0010272202) traded at 26.14 US dollars at the close on 2026-06-25 on Nasdaq.
Genmab key share data
- Company: Genmab A/S
- ISIN: DK0010272202
- WKN: 565131
- Ticker: GMAB
- Trading venue: Nasdaq
- Price (as of 2026-06-25, 16:00): 26.14 USD
- Market cap: 16.32 billion USD (as of 2026-06-25)
- Sector / industry: Biotechnology / biopharmaceutical products
- Index membership: Nasdaq Global Select Market
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instruments. Investors should conduct their own research and, where appropriate, consult a qualified financial adviser before making investment decisions.
